According to a new study utilizing an animal model, the marijuana-derived compound cannabidiol (CBD) was able to reduce the cognitive deficits associated with Fragile X Syndrome.

“Cannabidiol (CBD), a non-psychotomimetic constituent of Cannabis sativa, has been recently approved for epileptic syndromes often associated with Autism spectrum disorder (ASD)”, begins the study’s abstract. “However, the putative efficacy and mechanism of action of CBD in patients suffering from ASD and related comorbidities remain debated, especially because of the complex pharmacology of CBD.”
For this study, researchers “used pharmacological, immunohistochemical and biochemical approaches to investigate the effects and mechanisms of action of CBD in the recently validated rat model of ASD, that is also a model of Fragile X Syndrome (FXS), the leading monogenic cause of autism.”
Continue reading












